Keywords
Central Nervous System Stimulants
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: Demonstrate the approach of psychostimulants in binge eating disorder, considering not only the clinical aspects of the disorder, but also the social, cultural, and psychosocial contexts in which patients are inserted. Literature review: The impact of binge eating on individuals' quality of life is profound and multifaceted. In addition to adverse physical effects, such as increased risk of chronic diseases, episodes of binge eating can lead to feelings of shame and low self-esteem, significantly impairing patients' psychological and social well-being. Lisdexamfetamine is the first medication approved for the treatment of binge eating disorder, studies have shown a significant reduction in binge eating symptoms. However, the heterogeneity of available clinical studies may hinder the interpretation of results and the generalization of conclusions to the clinical practice of many medications. Final considerations: Therefore, it is possible to perceive that the use of psychostimulants in patients with binge eating disorder plays an important role, especially in patients who do not have good results with other therapies, such as psychotherapy or surgery. However, the need for more studies at various levels is evident.
References
APPOLINARIO JC, et al. Compulsão alimentar. In: Moura EC e Tufik S. (Eds.). Medicina do Sono. São Paulo: Atheneu, 2008; 489-498.
BLANCO-GANDIA MC, et al. Binge eating and psychostimulant addiction. World journal of psychiatry, 2021; 17(9): 517-529.
CITROME L. “Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.” International journal of clinical practice, 2015; 69(4): 410-21.
FERRARINI NO, et al. Alternativas terapêuticas farmacológicas para transtorno da compulsão alimentar: uma revisão sistemática. Debates em Psiquiatria, Rio de Janeiro. 2023;13: 1-15.
FORNARO M, et al. Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. Neuropsychiatric disease and treatment, 2016; 12: 1827–1836.
GOMES SB, et al. Evolução histórica dos conceitos e critérios diagnósticos da bulimia nervosa e do transtorno da compulsão alimentar: uma revisão de literatura. Diálogos Interdisciplinares em Psiquiatria e Saúde Mental, 2021; 1(1): 60-69.
GUERDJIKOVA AI, et al. Pharmacotherapy of binge-eating disorder: current and future directions. Expert Opinion on Pharmacotherapy, 2015; 16(10): 1469-1478.
HEAL DJ, et al. Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder. Advances in Pharmacology, 2023.
HILBERT A, et al. Meta-análise sobre a eficácia a longo prazo de tratamentos psicológicos e médicos para transtornos da compulsão alimentar periódica. Jornal internacional de distúrbios alimentares, 2020; 53(9): 13-53-1376.
HUDSON JI, et al. Implications of the DSM-5 binge eating disorder diagnosis for the DSM-IV diagnoses of morbid obesity and night eating syndrome. International Journal of Eating Disorders, 2010; 43(7): 603-611.
LEOMBRUNI P, et al. The Role of Methylphenidate in Treating Binge Eating Disorder: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021; 10(15): 3342.
LUCAS NNF, et al. Principais abordagens da terapia cognitivo-comportamental associadas às terapias farmacológicas no tratamento do transtorno de compulsão alimentar periódico. Seven Editora, 2023; 1794-1805.
MONTELEONE AM, et al. Pharmacological Treatment of Binge Eating Disorder: A Review of the Current Evidence and Future Directions. CNS Drugs, 2022; 36(1): 29-43.
MCELROY SL, et al. Pharmacological management of binge eating disorder. In: Agras WS, Robinson AH, editors. The Oxford Handbook of Eating Disorders. Oxford: Oxford University Press, 2012; 471–492.
MCELROY SL, et al. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology, 2016; 41(5): 1251-1260.
NOGUEIRA JP, et al. Compulsão alimentar periódica: uma revisão. Revista de Psiquiatria Clínica, 2005; 32(3): 140-146.
PARK E, et al. The Role of Pharmacotherapy in Binge Eating Disorder: A Systematic Review and Network Meta-Analysis. Clinical Psychopharmacology and Neuroscience, 2021; 19(1): 35-48.
PASTURA G e MATTOS P. Efeitos colaterais do metilfenidato. Revisão de Literatura. Revista de Psiquiatria Clínica 2004; 31: 100–104.
QUADROS MRR, et al. Compulsão alimentar em pacientes no pré-operatório de cirurgia bariátrica. Psicologia Argumento, 2006; 24(45): 59-65.
QUILTY LC, et al. A randomized comparison of long acting methylphenidate and cognitive behavioral therapy in the treatment of binge eating disorder. Psychiatry research, 2019; 273: 467–474.
RASTRELLI G, et al. Stimulant Medications for the Treatment of Binge Eating Disorder: A Review of Current Evidence and Future Perspectives. CNS Drugs, 2021; 35(12): 1319-1330.
SILVA LVS. Farmacoterapia do Transtorno do Déficit de Atenção. Universidade Federal de Santa Catarina, 2020; 28-31.